Telangana Targets $25 Billion Investment In Life Sciences By 2030

(MENAFN- IANS) Hyderabad, Jan 21 (IANS) The Telangana government has set the target of attracting $25 billion investment in life sciences in the next five years.

The government unveiled Telangana Next-Gen Life Sciences Policy 2026–2030 at Davos with a clear roadmap to position Telangana among the top five global life sciences clusters by 2030.

Chief Minister A. Revanth Reddy, who is leading a delegation of ministers and top officials at the World Economic Forum (WEF) annual meeting, released the policy.

Industry minister Sridhar Babu said that the policy targets $25 billion in investments and the creation of 5 lakh new jobs, with a strong focus on high-value R&D, advanced biologics and therapies, and environmentally sustainable manufacturing.

According to him, key initiatives include Green Pharma City, flagship Pharma Villages, and 1Bio, a first-of-its-kind growth-phase centre and biopharma scale-up manufacturing facility.

The State government will also establish a dedicated Life Sciences Innovation Fund, scalable up to Rs 1,000 crore ($111 million).

“With Hyderabad already home to the World Economic Forum's Fourth Industrial Revolution (C4IR) Network and the world's first centre focused on healthcare and life sciences, Telangana is uniquely positioned to lead the next wave of global life sciences innovation. We are building a future-ready ecosystem that is science-led, sustainable, and globally competitive,” the minister said.

By leveraging its established strengths in pharmaceutical manufacturing, vaccine production, and R&D, while strategically diversifying into emerging fields such as biologics, precision medicine, and biomanufacturing, Telangana is poised to redefine healthcare and life sciences innovation, says the policy document.

Telangana currently contributes 40 per cent of India's pharmaceutical production. The state is the only region in the world housing over 250 USFDA-approved manufacturing sites.

The state has also earned the reputation of being the vaccine capital of the world and played a key role in saving millions of lives during the COVID-19 pandemic. With a total vaccine production capacity of approximately 14 billion doses, it has solidified its leadership position as a global vaccine hub.

The state is also emerging as a leader in the manufacturing of medical devices and diagnostic equipment/reagents with a flourishing ecosystem.

MENAFN21012026000231011071ID1110630155